KSQ Therapeutics Stock

ksqtx.comHealthcareFounded: 2015Funding to Date: $257.46MM

KSQ Therapeutics is the developer of a genome-scale precision functional genomics platform, called CRISPRomics, designed to pinpoint therapeutic nodes that directly correlate genomic function to disease with unprecedented certainty and speed.

Register for Details

For more details on financing and valuation for KSQ Therapeutics, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

By registering, you agree to the Forge Terms of Use. Already registered? Click here to log in

Enterprise Value (based on primary financings)

Enterprise Value

View Enterprise Value for KSQ Therapeutics.

Register Today

Team

Management Team

David Meeker MD
Chief Executive Officer & Board Member
David Sabatini Ph.D
Co-Founder
Jonathan Weissman Ph.D
Co-Founder
John Trzupek Ph.D
Interim Chief Financial Officer & Head, Corporate Development
William Hahn MD
Co-Founder
Frank Stegmeier Ph.D
Chief Scientific Officer
Tim Wang Ph.D
Co-Founder

Board Members

David Meeker MD
George Golumbeski Ph.D
David Berry Ph.D
Flagship Pioneering
Pearl Huang Ph.D
Theo Melas-Kyriazi
Alan Crane
Polaris Partners
James Gilbert
Flagship Pioneering
Richard Moscicki MD

Other companies like KSQ Therapeutics in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.6B
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$150MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$296.3MM
Sector
Last Round Est. Valuation
$4.8B

News

KSQ Therapeutics, a biotechnology company using CRISPR technology to enable the company’s powerful discovery engine to achieve higher probabilities of